Abstract 3683
Background
The impact of radiotherapy (RT) on the efficacy and toxicity of immune checkpoint inhibitors in patients (pts) with metastatic non-small cell-lung cancer (NSCLC) is unclear.
Methods
We retrospectively identified pts with metastatic NSCLC treated with the anti-programmed death 1 (PD-1) antibodies nivolumab or pembrolizumab between January 2016 and May 2019 at two major oncology centres in Melbourne, Australia. Patient demographics, tumour characteristics, treatment history including radiotherapy (RT) use and toxicity were collected. Disease control rate (DCR), progression free survival (PFS) and overall survival (OS) were analysed and correlated with RT use.
Results
132 pts identified with interim analysis of 54 reported here. Median follow up was 19.4 months. Majority were male (61%) and 87% were smokers. 80% had non-squamous histology, of these 9% had an EGFR mutation. Brain metastases were present in 41%. The median number of cycles of anti-PD1 treatment received was 5 and only 7% started anti-PD-1 as first-line therapy. 36% received RT treatment either during or within 3 months of starting anti-PD1 treatment. Of patients that received RT, 74% were treated with extra-thoracic RT. The use of RT before or during anti-PD1 treatment did not result in an increase in high grade immune-related adverse events. The DCR was 35%. The median PFS was 2 months (95% CI 0.5 – 29) and OS 9.7 months (95% CI 1.0 – 31). Pts who received RT had a numerically shorter PFS than those that did not (1.5 vs 2 months, p = 0.668) but numerically longer OS (8.1 vs 7.2 months, p = 0.857). Updated analysis with the full cohort and with longer follow-up will be presented.
Conclusions
Radiotherapy did not significantly impact on survival in pts with metastatic NSCLC treated with anti-PD1 therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4369 - Biomarker testing of lung cancer in Spain
Presenter: Delvys Rodriguez Abreu
Session: Poster Display session 1
Resources:
Abstract
603 - Mendelian Randomization Study of Alzheimer's Disease and Lung Cancer
Presenter: Huaqiang Zhou
Session: Poster Display session 1
Resources:
Abstract
4462 - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer
Presenter: Rafael Lopez Castro
Session: Poster Display session 1
Resources:
Abstract
3957 - Pleural effusion TGF-beta is highly diagnostic and prognostic in malignant pleural mesothelioma
Presenter: Paul Stockhammer
Session: Poster Display session 1
Resources:
Abstract
3583 - Immune microenvironment modulation by p14/ARF in Malignant Pleural Mesothelioma
Presenter: Giulia Pasello
Session: Poster Display session 1
Resources:
Abstract
4255 - Tumor Treating Fields plus chemotherapy for first-line malignant pleural mesothelioma (MPM): radiological responses in the STELLAR trial
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract
1803 - Effects of Tumor Treating Fields (TTFields; 150 kHz) and Cisplatin or Pemetrexed Combination Therapy on Mesothelioma cells In Vitro and In Vivo
Presenter: Mijal Munster
Session: Poster Display session 1
Resources:
Abstract
2660 - Real world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)
Presenter: Susana Cedres
Session: Poster Display session 1
Resources:
Abstract
3150 - Pemetrexed/Cisplatin versus Gemcitabine/Cisplatin as first-line treatment for Egyptian patients with malignant pleural mesothelioma
Presenter: Mohamed Alorabi
Session: Poster Display session 1
Resources:
Abstract
4319 - Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference Centre
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract